Education
About Us
Working with TipRanks
Follow Us
REPRO-MED Systems (KRMD)
NASDAQ:KRMD
Top Page
REPRO-MED Systems
(NASDAQ:KRMD)
Rating:60Neutral
Price Target:
$3.00
▲( 10.29% Upside)
Positive Factors
Financial Performance
KRMD delivered a strong quarter as it beat on revenue and margin expectations, seeing material outperformance in its OUS markets.
Growth Opportunities
KRMD raised its revenue guidance reflecting growth of now 15-17%, underpinned by SCIg market growth, global share gains, NRE revenue from new expected collaborations, flow controller line extension, and Japan market entry.
Product Innovation
The new product initiative is focused on an easier-to-use and more comfortable pump and disposable infusion set.
Negative Factors
Competitive Pressures
There is wariness of the potential for competitive pressures to expand going forward.
REPRO-MED Systems (KRMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$136.12M
Dividend YieldN/A
Average Volume (3M)134.80K
Price to Earnings (P/E)―
Beta (1Y)0.67
Revenue Growth19.65%
EPS Growth60.28%
CountryUS
Employees80
SectorHealthcare
Sector Strength43
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.00
Shares Outstanding46,140,995
10 Day Avg. Volume138,337
30 Day Avg. Volume134,798
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)6.92
Price to Sales (P/S)0.00
P/FCF Ratio-72.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.83Price Target Upside77.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
REPRO-MED Systems Business Overview & Revenue Model
Company DescriptionREPRO-MED Systems, Inc. (KRMD), also known as KORU Medical Systems, is a medical technology company specializing in the development and manufacturing of innovative infusion solutions. The company is primarily focused on producing portable and user-friendly infusion systems, which are used for the delivery of subcutaneous medications in the home and alternate care settings. KORU Medical Systems is known for its FREEDOM System, which includes the FREEDOM60 and FREEDOMEdge pumps, as well as a range of related accessories designed to enhance patient comfort and convenience.
How the Company Makes MoneyREPRO-MED Systems generates revenue through the sale of its proprietary infusion systems, including the FREEDOM60 and FREEDOMEdge pumps, along with associated accessories such as tubing and needle sets. The company's revenue model is based on direct sales to healthcare providers, distributors, and patients for home infusion therapies. Key revenue streams include repeat sales of consumable products that are essential for the operation of the infusion systems. Additionally, significant partnerships with healthcare providers and distributors contribute to its earnings by expanding its market reach and facilitating product adoption within the home healthcare sector. The company's focus on user-friendly and cost-effective solutions supports its growth and profitability in the competitive medical device industry.
REPRO-MED Systems Financial Statement Overview
Summary
REPRO-MED Systems shows strong revenue growth but struggles with profitability. The balance sheet indicates low leverage but poor return on equity. Cash flow management is improving, but negative operating cash flow highlights ongoing financial strain.Income Statement
REPRO-MED Systems has shown revenue growth from 2023 to 2024, with a Revenue Growth Rate of 18%. However, the Net Profit Margin remains negative due to consistent losses, with a Net Income of -$6.07 million in 2024. Gross Profit Margin is improving but still offset by negative EBIT and EBITDA margins, indicating operational challenges.45
Neutral
Balance Sheet
The balance sheet shows a moderate Debt-to-Equity Ratio as Total Debt is relatively low compared to Stockholders' Equity. With a Debt-to-Equity Ratio of 0.22, the company maintains a stable equity base. However, Return on Equity is negative due to ongoing losses, indicating inefficiency in using shareholders' investments to generate profits.60
Neutral
Cash Flow
Cash flow analysis shows improvement in Free Cash Flow from -$5.71 million in 2023 to -$1.62 million in 2024, reflecting efforts to manage expenditures. Nonetheless, Operating Cash Flow remains negative, highlighting continued cash flow challenges. The company shows a Free Cash Flow to Net Income Ratio of 0.27, signifying some ability to convert earnings into cash flow.50
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 33.65M | 28.52M | 27.90M | 23.49M | 24.18M | Gross Profit |
| 21.33M | 16.71M | 15.37M | 13.77M | 14.94M | EBIT |
| -5.56M | -10.27M | -10.78M | -7.03M | -1.25M | EBITDA |
| -5.56M | -9.40M | -10.19M | -6.57M | 1.61M | Net Income Common Stockholders |
| -6.07M | -13.74M | -8.66M | -4.56M | -1.21M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 9.58M | 11.48M | 17.41M | 25.33M | 27.32M | Total Assets |
| 27.22M | 28.46M | 42.33M | 41.29M | 39.92M | Total Debt |
| 3.72M | 4.45M | 4.93M | 604.14K | 239.49K | Net Debt |
| -5.86M | -7.04M | -12.48M | -24.73M | -27.08M | Total Liabilities |
| 10.40M | 8.11M | 11.01M | 4.79M | 3.76M | Stockholders Equity |
| 16.81M | 20.35M | 31.33M | 36.50M | 36.16M |
| Cash Flow | Free Cash Flow | |||
| -1.62M | -5.71M | -8.21M | -4.69M | -1.80M | Operating Cash Flow |
| -319.72K | -4.89M | -5.40M | -4.32M | -743.32K | Investing Cash Flow |
| -1.33M | -814.60K | -2.80M | -366.17K | -1.04M | Financing Cash Flow |
| -248.53K | -218.87K | 279.49K | 2.71M | 23.22M |
REPRO-MED Systems Technical Analysis
Negative
2.72
Price Trends
2.67
Negative
3.31
Negative
3.12
Negative
Market Momentum
0.04
Positive
43.51
Neutral
3.89
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRMD, the sentiment is Negative. The current price of 2.72 is below the 20-day moving average (MA) of 2.89, above the 50-day MA of 2.67, and below the 200-day MA of 3.12, indicating a bearish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 43.51 is Neutral, neither overbought nor oversold. The STOCH value of 3.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KRMD.
REPRO-MED Systems Risk Analysis
REPRO-MED Systems disclosed 47 risk factors in its most recent earnings report. REPRO-MED Systems reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
REPRO-MED Systems Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $121.66M | 39.51 | 5.94% | ― | 7.98% | 3304.55% | |
67 Neutral | $174.30M | 14.21 | 10.59% | 2.27% | -19.92% | ― | |
60 Neutral | $136.12M | ― | -29.87% | ― | 19.65% | 60.28% | |
53 Neutral | $5.14B | 3.06 | -43.57% | 2.81% | 16.81% | -0.12% | |
48 Neutral | $75.84M | ― | -88.36% | ― | -9.13% | 30.04% | |
43 Neutral | $19.16M | ― | -25.89% | ― | -16.05% | -195.28% |
* Healthcare Sector Average
Performance Comparison
KRMD
REPRO-MED Systems
2.72
0.52
23.64%
INFU
InfuSystem Holdings
5.41
-1.74
-24.34%
RVP
Retractable Technologies
0.65
-0.29
-30.85%
UTMD
Utah Medical Products
53.66
-12.08
-18.38%
MLSS
Milestone Scientific
0.97
0.22
29.33%
REPRO-MED Systems Earnings Call Summary
Earnings Call Date:May 07, 2025
(Q1-2025)
| % Change Since: 0.00%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
KORU Medical Systems reported strong growth across its core and international business segments, leading to record revenues and an improved gross margin. The company raised its revenue guidance for 2025, demonstrating confidence in continued growth. Despite some challenges in clinical trials revenue and tariff impacts, the overall performance and strategic progress are positive.Q1-2025 Updates
Positive Updates
Record Revenue Growth
KORU Medical Systems achieved a record revenue of $9.6 million for the first quarter of 2025, representing an 18% increase over the prior year.
Core Business Expansion
The core business grew 21% in the quarter, driven by new patient starts, increased market share, and deeper penetration into new and existing geographies.
International Growth
International business achieved 36% growth, driven by patient growth and new distributor relationships in the Middle East and North Africa.
Gross Margin Improvement
Reported gross margin improved by 50 basis points to 62.8% compared to the previous year.
Raised 2025 Revenue Guidance
The company raised its 2025 revenue guidance to a range of $38.5 million to $39.5 million, representing a 15% to 17% year-over-year growth.
Pipeline Expansion
Plans to submit two additional commercialized drugs for 510(k) clearance for the Freedom Infusion System by the end of 2025, bringing the total pipeline to five planned submissions.
Positive Cash Flow Expectation
The company expects to generate positive cash flow from operations in 2025.
Prefilled Syringe Tender Win
Secured a key prefilled syringe tender win with a major pharmaceutical partner in the EU, marking a significant milestone.
Negative Updates
Decline in Pharma Services and Clinical Trials Revenue
Pharma Services and Clinical Trials revenues declined by 39% compared to the prior year due to lower clinical trial orders.
Impact of Tariffs
Tariffs are expected to have a nearly 100 basis point impact on gross margins for the year.
Company Guidance
During the call, KORU Medical Systems provided updated guidance for fiscal year 2025, reflecting a robust performance in the first quarter. The company reported a record revenue of $9.6 million for Q1, marking an 18% increase compared to the previous year. This growth was driven by a 21% increase in their core business, attributed to recurring revenue, new patient starts, and increased market share. As a result, KORU raised its full-year revenue guidance to a range of $38.5 million to $39.5 million, representing a year-over-year growth of 15% to 17%. The company also reaffirmed its gross margin target of 61% to 63% and expects to generate positive cash flow from operations in 2025. Additionally, they plan to submit two more drugs for 510(k) clearance by the end of the year, expanding their pipeline to five planned submissions.REPRO-MED Systems Corporate Events
Executive/Board ChangesShareholder Meetings
REPRO-MED Systems Holds Annual Shareholder Meeting
Neutral
May 15, 2025
On May 14, 2025, REPRO-MED Systems held its Annual Meeting of Shareholders where key decisions were made regarding the company’s governance and financial oversight. Shareholders elected the proposed nominees to the board of directors, approved executive compensation on an advisory basis, and ratified the appointment of Cherry Bekaert LLP as the independent registered public accountants for the 2025 fiscal year.
The most recent analyst rating on (KRMD) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on REPRO-MED Systems stock, see the KRMD Stock Forecast page.
Executive/Board ChangesBusiness Operations and Strategy
KORU Medical’s CCO Resigns, Interim Leader Appointed
Neutral
Apr 7, 2025
On April 3, 2025, Kenneth Miller resigned as Chief Commercial Officer of KORU Medical Systems to pursue a CEO role elsewhere. Rob Cannon, with extensive experience in healthcare sales, will temporarily lead the company’s commercial operations. Despite the leadership change, KORU Medical maintains its 2025 revenue guidance of $38.0-$39.0 million.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.